ClinicaliQ Trial Snapshot
- Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis — Recruiting • Phase III • Rheumatology • NCT04804553.
- Apremilast was tested against placebo in children aged 5-17 with juvenile psoriatic arthritis to assess its effectiveness.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The study will aim to estimate the efficacy of apremilast compared with placebo in the treatment of juvenile psoriatic arthritis (JPsA) in pediatric participants 5 to less than 18 years of age. Conditions: Active Juvenile Psoriatic Arthritis Interventions: Apremilast, Placebo Lead Sponsor: Amgen Planned Enrollment: 60 participants